MedTrace Logo

A Trial of SHR-1905 in Healthy Subjects

NCT04800263 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-05-10

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, single dose escalation phase 1 study. The objective of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of subcutaneous administered SHR-1905 in healthy subjects.

Conditions

Interventions

DRUG

SHR-1905

SHR-1905 will be injected subcutaneously

DRUG

Placebo

Placebo will be injected subcutaneously

Sponsors & Collaborators

  • Atridia Pty Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-27
Primary Completion
2022-11-12
Completion
2022-11-12

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04800263 on ClinicalTrials.gov